Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

CRISPR-mediated modeling and functional validation of candidate tumor suppressor genes in small cell lung cancer.

Ng SR, Rideout WM 3rd, Akama-Garren EH, Bhutkar A, Mercer KL, Schenkel JM, Bronson RT, Jacks T.

Proc Natl Acad Sci U S A. 2020 Jan 7;117(1):513-521. doi: 10.1073/pnas.1821893117. Epub 2019 Dec 23.

2.

A Modular Assembly Platform for Rapid Generation of DNA Constructs.

Akama-Garren EH, Joshi NS, Tammela T, Chang GP, Wagner BL, Lee DY, Rideout WM 3rd, Papagiannakopoulos T, Xue W, Jacks T.

Sci Rep. 2016 Feb 18;6:16836. doi: 10.1038/srep16836.

3.

Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.

Faber AC, Farago AF, Costa C, Dastur A, Gomez-Caraballo M, Robbins R, Wagner BL, Rideout WM 3rd, Jakubik CT, Ham J, Edelman EJ, Ebi H, Yeo AT, Hata AN, Song Y, Patel NU, March RJ, Tam AT, Milano RJ, Boisvert JL, Hicks MA, Elmiligy S, Malstrom SE, Rivera MN, Harada H, Windle BE, Ramaswamy S, Benes CH, Jacks T, Engelman JA.

Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1288-96. doi: 10.1073/pnas.1411848112. Epub 2015 Mar 3.

4.

Microenvironment-derived HGF overcomes genetically determined sensitivity to anti-MET drugs.

Pennacchietti S, Cazzanti M, Bertotti A, Rideout WM 3rd, Han M, Gyuris J, Perera T, Comoglio PM, Trusolino L, Michieli P.

Cancer Res. 2014 Nov 15;74(22):6598-609. doi: 10.1158/0008-5472.CAN-14-0761. Epub 2014 Sep 12.

5.

Spontaneous genomic alterations in a chimeric model of colorectal cancer enable metastasis and guide effective combinatorial therapy.

Zhou Y, Rideout WM 3rd, Bressel A, Yalavarthi S, Zi T, Potz D, Farlow S, Brodeur J, Monti A, Reddipalli S, Xiao Q, Bottega S, Feng B, Chiu MI, Bosenberg M, Heyer J.

PLoS One. 2014 Aug 27;9(8):e105886. doi: 10.1371/journal.pone.0105886. eCollection 2014.

6.

MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors.

Luraghi P, Reato G, Cipriano E, Sassi F, Orzan F, Bigatto V, De Bacco F, Menietti E, Han M, Rideout WM 3rd, Perera T, Bertotti A, Trusolino L, Comoglio PM, Boccaccio C.

Cancer Res. 2014 Mar 15;74(6):1857-69. doi: 10.1158/0008-5472.CAN-13-2340-T. Epub 2014 Jan 21.

7.

Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas.

Zhou Y, Rideout WM 3rd, Zi T, Bressel A, Reddypalli S, Rancourt R, Woo JK, Horner JW, Chin L, Chiu MI, Bosenberg M, Jacks T, Clark SC, Depinho RA, Robinson MO, Heyer J.

Nat Biotechnol. 2010 Jan;28(1):71-8. doi: 10.1038/nbt.1595. Epub 2009 Dec 20.

PMID:
20023657
8.

Global loss of imprinting leads to widespread tumorigenesis in adult mice.

Holm TM, Jackson-Grusby L, Brambrink T, Yamada Y, Rideout WM 3rd, Jaenisch R.

Cancer Cell. 2005 Oct;8(4):275-85. Erratum in: Cancer Cell. 2005 Nov;8(5):433. Cancer Cell. 2006 Jan;9(1):69.

9.

Nuclear transplantation, embryonic stem cells and the potential for cell therapy.

Hochedlinger K, Rideout WM, Kyba M, Daley GQ, Blelloch R, Jaenisch R.

Hematol J. 2004;5 Suppl 3:S114-7. Review.

PMID:
15190291
10.

Cyclin E ablation in the mouse.

Geng Y, Yu Q, Sicinska E, Das M, Schneider JE, Bhattacharya S, Rideout WM, Bronson RT, Gardner H, Sicinski P.

Cell. 2003 Aug 22;114(4):431-43.

11.

Nuclear cloning, stem cells, and genomic reprogramming.

Jeanisch R, Eggan K, Humpherys D, Rideout W, Hochedlinger K.

Cloning Stem Cells. 2002;4(4):389-96. Review.

PMID:
12630413
12.

Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy.

Rideout WM 3rd, Hochedlinger K, Kyba M, Daley GQ, Jaenisch R.

Cell. 2002 Apr 5;109(1):17-27.

PMID:
11955443

Supplemental Content

Loading ...
Support Center